← Back to Search

Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19)

Phase 2

Waitlist Available

Led By Bentley J. Bobrow, MD

Research Sponsored by The University of Texas Health Science Center, Houston

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up day 14

Summary

This trial is testing vadadustat, a medication that may help prevent or treat severe lung problems in hospitalized COVID-19 patients. The drug works by helping the body handle low oxygen levels better. The goal is to see if it can reduce the risk or severity of acute respiratory distress syndrome (ARDS).

Eligible Conditions

Coronavirus
Acute Respiratory Distress Syndrome

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ day 14

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~day 14

This trial's timeline: 3 weeks for screening, Varies for treatment, and day 14 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Number of participants who are classified 8 (dead), 7 (hospitalized, on invasive mechanical ventilation or ECMO), or 6 (hospitalized, on non-invasive ventilation or high flow oxygen devices) on the NIAID ordinal scale

Secondary study objectives

Number of participants with a total score of 0 on the Modified Sequential Organ Failure Assessment (MSOFA) scale

Other study objectives

Number of participants with hypotension

Score on the Modified Sequential Organ Failure Assessment (MSOFA) scale